Skip to main content
Erschienen in: The Journal of Obstetrics and Gynecology of India 5/2023

30.09.2023 | Original Article

Survival Rate in Cancer Cervix Patients in a Regional Cancer Centre of South India: A Retrospective Analysis

verfasst von: Sakthi Usha Devi Jeevarajan, Prasanna Srinivasa Rao Harikrishnan, T. D. Balamurugan, Ajay Kumar Arunachalam

Erschienen in: The Journal of Obstetrics and Gynecology of India | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Context

Carcinoma Cervix is one of the leading prevalent cancers in India especially in rural population and causes a significant mortality. WHO has launched many projects for prevention, screening and treatment plans. Even after many projects, Cervical Cancer persists as a heavy burden public health problem in rural India.

Aims

To calculate survival of cancer cervix patients in a rural population-based RCC and to discuss the factors affecting it.

Methods and Material

A hospital-based gathering of retrospective data of the patients diagnosed with carcinoma cervix over 5 years from January 2013 to December 2017 (single institution analysis). We included 751 patient’s data from our cancer registry for analysis. Data related to demographics, treatment and follow up records were taken and statistical analysis done.

Results

The survival rates were 64.0%, 50.0%, 36.9% and 17.5% for Stage I, Stage II, Stage III and Stage IV, respectively. The best survival outcomes were for those treated with only surgery. Involvement of nodes had poor survival than those with no involvement. Various patient-related factors like Religion, Education and Marital status are found to be non-significant factors even-though they have survival differences. STAGE of the disease emerged as a significant prognostic factor.

Conclusion

Our study concluded that higher stage and nodal involvement had poor outcomes and also lower survival compared to Western and Indian literature. We should also address all the socio-economic factors that affects survival. Randomized prospective studies are needed to evaluate the effect of socio-economic factors on survival.
Literatur
1.
Zurück zum Zitat Hyuna S, Jacques F, Rebecca LS, Mathieu L, Isabelle S, Ahmedin J. GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRef Hyuna S, Jacques F, Rebecca LS, Mathieu L, Isabelle S, Ahmedin J. GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRef
3.
Zurück zum Zitat Federico C, Alleyn J, Dola C, et al. Relationship among age, race, medical funding, and cervical cancer survival. J Natl Med Assoc. 2010;102:199–205.PubMed Federico C, Alleyn J, Dola C, et al. Relationship among age, race, medical funding, and cervical cancer survival. J Natl Med Assoc. 2010;102:199–205.PubMed
4.
Zurück zum Zitat Sankaranarayanan R, Swaminathan R. Cancer Survival in Africa, Asia, the Carribbean and Central America. IARC Scientific Publications No. 162. Lyon: International Agency for Research on Cancer; 2011. Sankaranarayanan R, Swaminathan R. Cancer Survival in Africa, Asia, the Carribbean and Central America. IARC Scientific Publications No. 162. Lyon: International Agency for Research on Cancer; 2011.
5.
Zurück zum Zitat Kaku M, Mathew A, Rajan B. Impact of socio-economic factors in delayed reporting and late-stage presentation among patients with cervix cancer in a major cancer hospital in South India. Asian Pac J Cancer Prev. 2008;9(4):589–94.PubMed Kaku M, Mathew A, Rajan B. Impact of socio-economic factors in delayed reporting and late-stage presentation among patients with cervix cancer in a major cancer hospital in South India. Asian Pac J Cancer Prev. 2008;9(4):589–94.PubMed
6.
Zurück zum Zitat Balasubramaniam G, Gaidhani R, Khan A, Saoba S, Mahantshetty U, Maheshwari A. Survival rate of cervical cancer from a study conducted in India. Indian J Med Sci. 2020;73:1–10. Balasubramaniam G, Gaidhani R, Khan A, Saoba S, Mahantshetty U, Maheshwari A. Survival rate of cervical cancer from a study conducted in India. Indian J Med Sci. 2020;73:1–10.
7.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 Lyon, France: International Agency for Research on Cancer; 2010 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 Lyon, France: International Agency for Research on Cancer; 2010
8.
Zurück zum Zitat Coker AL, Du XL, Fang S, Eggleston KS. Socioeconomic status and cervical cancer survival among older women: findings from the SEER-Medicare linked data cohorts. Gynecol Oncol. 2006;102(2):278–84.CrossRefPubMed Coker AL, Du XL, Fang S, Eggleston KS. Socioeconomic status and cervical cancer survival among older women: findings from the SEER-Medicare linked data cohorts. Gynecol Oncol. 2006;102(2):278–84.CrossRefPubMed
9.
Zurück zum Zitat Nandakumar A, Anantha N, Venugopal TC. Incidence, mortality and survival in cancer of the cervix in Bangalore. India Br J Cancer. 1995;71(6):1348–52.CrossRefPubMed Nandakumar A, Anantha N, Venugopal TC. Incidence, mortality and survival in cancer of the cervix in Bangalore. India Br J Cancer. 1995;71(6):1348–52.CrossRefPubMed
10.
Zurück zum Zitat Munagala R, Rai SN, Ganesharajah S, Bala N, Gupta RC. Clinicopathological, but not socio-demographic factors affect the prognosis in cervical carcinoma. Oncol Rep. 2010;24(2):511–20.PubMed Munagala R, Rai SN, Ganesharajah S, Bala N, Gupta RC. Clinicopathological, but not socio-demographic factors affect the prognosis in cervical carcinoma. Oncol Rep. 2010;24(2):511–20.PubMed
11.
Zurück zum Zitat Coker AL, Du XL, Fang S, Eggleston KS. Socioeconomic status and cervical cancer survival among older women: findings from the SEER-Medicare linked data cohorts. Gynecol Oncol. 2006;102(2):278–84.CrossRefPubMed Coker AL, Du XL, Fang S, Eggleston KS. Socioeconomic status and cervical cancer survival among older women: findings from the SEER-Medicare linked data cohorts. Gynecol Oncol. 2006;102(2):278–84.CrossRefPubMed
12.
Zurück zum Zitat Sankaranarayanan R, Nair MK, Jayaprakash PG, Stanley G, Varghese C, Ramadas V, Padmakumary G, et al. Cervical cancer in Kerala: a hospital registry-based study on survival and prognostic factors. Br J Cancer. 1995;72(4):1039–42.CrossRefPubMedPubMedCentral Sankaranarayanan R, Nair MK, Jayaprakash PG, Stanley G, Varghese C, Ramadas V, Padmakumary G, et al. Cervical cancer in Kerala: a hospital registry-based study on survival and prognostic factors. Br J Cancer. 1995;72(4):1039–42.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Yeole BB, Sankaranarayanan R, Jussawalla DJ. Long-term survival from uterine cervical cancer in Mumbai (Bombay). India Int J Cancer. 1998;78:394–5.CrossRefPubMed Yeole BB, Sankaranarayanan R, Jussawalla DJ. Long-term survival from uterine cervical cancer in Mumbai (Bombay). India Int J Cancer. 1998;78:394–5.CrossRefPubMed
14.
Zurück zum Zitat Sriamporn S, Black RJ, Sankaranarayanan R, Kamsa-Ad S, Parkin DM, Vatanasapt V. Cancer survival in Khon Kaen Province. Thailand Int J Cancer. 1995;61:296–300.CrossRefPubMed Sriamporn S, Black RJ, Sankaranarayanan R, Kamsa-Ad S, Parkin DM, Vatanasapt V. Cancer survival in Khon Kaen Province. Thailand Int J Cancer. 1995;61:296–300.CrossRefPubMed
15.
Zurück zum Zitat Sankaranarayanan R, Swaminathan R, Black RJ. Global variations in cancer survival, Study group on cancer survival in developing countries. Cancer. 1996;78:2461–4.CrossRefPubMed Sankaranarayanan R, Swaminathan R, Black RJ. Global variations in cancer survival, Study group on cancer survival in developing countries. Cancer. 1996;78:2461–4.CrossRefPubMed
16.
Zurück zum Zitat Jayant K, Rao RS, Nene BM, Dale PS, Nandakumar A. Improved survival in cervical cancer cases in a rural Indian population. Br J Cancer. 1996;74:285–7.CrossRefPubMedPubMedCentral Jayant K, Rao RS, Nene BM, Dale PS, Nandakumar A. Improved survival in cervical cancer cases in a rural Indian population. Br J Cancer. 1996;74:285–7.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Thulaseedharan JV, Malila N, Swaminathan R, Esmy PO, Hakama M, Muwonge R, et al. Survival of patients with cervical cancer in rural India. J Clin Gynecol Obstetr. 2015;4:290–6.CrossRef Thulaseedharan JV, Malila N, Swaminathan R, Esmy PO, Hakama M, Muwonge R, et al. Survival of patients with cervical cancer in rural India. J Clin Gynecol Obstetr. 2015;4:290–6.CrossRef
Metadaten
Titel
Survival Rate in Cancer Cervix Patients in a Regional Cancer Centre of South India: A Retrospective Analysis
verfasst von
Sakthi Usha Devi Jeevarajan
Prasanna Srinivasa Rao Harikrishnan
T. D. Balamurugan
Ajay Kumar Arunachalam
Publikationsdatum
30.09.2023
Verlag
Springer India
Erschienen in
The Journal of Obstetrics and Gynecology of India / Ausgabe 5/2023
Print ISSN: 0971-9202
Elektronische ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-023-01843-y

Weitere Artikel der Ausgabe 5/2023

The Journal of Obstetrics and Gynecology of India 5/2023 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.